In a rare occurrence in the A-share market, two companies recently announced that their directors or actual controllers are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations related to information disclosure of shareholding changes. Dian Diagnostics Group Co.,Ltd. and Hangzhou Tigermed Consulting Co.,Ltd. disclosed these developments, with TIGERMED's actual controllers, Ye Xiaoping and Cao Xiaochun, both being investigated, placing the leading CRO firm with a market cap of 42.2 billion yuan under intense scrutiny.

What risks and issues lie beneath the seemingly calm announcements?

1. Legacy Information Disclosure Issues Surface, Compliance Gaps Remain Unaddressed The core focus of these investigations is highly consistent: violations in information disclosure during shareholding changes. TIGERMED acknowledged in its announcement that its two controllers "issued corresponding announcements for each reduction," but later noted that "the information disclosure obligors have also supplemented the disclosure of the 'Brief Report on Changes in Rights and Interests'." The term "supplemented disclosure" is a significant risk indicator, suggesting potential failures in timely, accurate, or complete disclosure when the shareholding changes occurred.

If intentional concealment or major omissions are confirmed, Ye Xiaoping and Cao Xiaochun could face fines, market entry bans, or even trigger civil compensation from investors. As a dual-listed company on the A-share and Hong Kong markets, the investigation into its controllers will directly impact TIGERMED's refinancing efficiency, trust in overseas collaborations, and H-share valuation logic.

2. TIGERMED's Core Business Loses Focus: Net Profit Polished by Investments, Non-GAAP Net Profit Halved The investigation is not an isolated incident. TIGERMED's recent financial data reveals deeper operational concerns. Its 2025 annual report showed a net profit attributable to shareholders of 888 million yuan, a significant increase of 119.15% year-on-year, seemingly indicating a return to high growth. However, its non-GAAP net profit was only 355 million yuan, plummeting 58.47% year-on-year. This means over 60% of profits came from investment income and fair value changes, not from its core clinical CRO business.

In the first quarter of 2026, the issue became more apparent: net profit fell 70.36% year-on-year to 49.04 million yuan, while non-GAAP net profit saw only a slight increase of 17.65%. The sharp fluctuations in the profit statement indicate an excessive reliance on investment assets and severe instability in the profitability of its core business.

3. Investigation of Dual Core Controllers Damages Corporate Governance and Market Confidence Ye Xiaoping and Cao Xiaochun collectively hold 26.54% of shares and have signed a "Consensus Action Agreement," making them the absolute decision-making core of TIGERMED. The simultaneous investigation of both controllers is extremely rare in China's capital markets, with impacts extending far beyond potential fines. The controllers may face administrative penalties or restrictions on share transfers, affecting the efficiency of major strategic decisions. Investors are likely to question the company's governance transparency and internal control compliance systems, while overseas institutional investors may reduce or halt H-share purchases due to compliance risks.

For Dian Diagnostics, although the company quickly distanced itself, stating that Ye Xiaoping's investigation is unrelated to its operations and that he holds no shares or receives no salary from the company, his role as a director represents industry resources and endorsement. This incident may still weaken external trust in Dian Diagnostics' governance independence, particularly as a negative factor in institutional investor due diligence.

4. Industry Winter Persists, Compliance is the True "Moat" Over the past three years, the biopharmaceutical sector has faced a financing winter and intensified competition in clinical CROs, shifting from "high-speed growth" to a painful transition toward "high-quality survival." Although TIGERMED maintains its leading domestic market share, the exposure of its controllers' information disclosure flaws coincides with a sensitive period of performance pressure and valuation adjustments.

This is no coincidence. When growth stories lose their appeal, regulators and the market turn their attention to compliance details. Any historical gaps in equity change disclosures may be scrutinized word by word in the future.

For all listed companies, this incident sends a clear signal: regulatory requirements for "key minorities" have escalated from "post-facto remedies" to "full-cycle penetration." Directors and controllers are not merely figureheads but bearers of dual legal obligations and credit endorsements.

Conclusion The final outcome of Ye Xiaoping's case awaits regulatory investigation. Regardless of the result, the announcements from TIGERMED and Dian Diagnostics have sounded an alarm for the A-share market: under the principles of rule of law and market reverence, compliance is never a stumbling block to development but the only true moat for enterprises.